Good news in the fight against breast cancer. A study published in "The Lancet Oncology" finds that when two cancer drugs join forces they significantly reduce tumor size.
Women with "Her-2 Positive" breast cancer were treated with a combination of both drugs. After six weeks, those patients had tumors 22 percent smaller than women taking either drug alone.
Herceptin is already approved for breast cancer. Tykerb has only been used for treatment of advanced cancer. This is the first time they have been tested together.